Baxter International, Inc. Says FDA Lung Drug Promotion Misleading

September 1, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Aug 31 (Reuters) - U.S. health officials have issued a warning to Baxter International Inc (BAX.N) for misleading patients and doctors about the benefits of its Aralast lung drug.

Twitter
LinkedIn
Facebook
Email
Print

Baxter International, Inc. Food and Drug Administration (FDA)